Sec. 307. Accelerating timeline for breakthrough and RMAT designations
228 words·~1 min read·
/bill/117/hr/6000/ih/section-307·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 506(a)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(a)(2) ) is amended by striking A request for the designation may be made concurrently with, or at any time after, the submission of an application for the investigation of the drug under section 505(i) or section 351(a)(3) of the Public Health Service Act and inserting A request for the designation may be made at any point before or after submission of an application for approval of the drug under section 505(b) of this Act or licensure of the drug under section 351(a)(2) of the Public Health Service Act and shall include clinical evidence, including preliminary clinical evidence from clinical trials conducted outside of the United States .
Section 506(g)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(g)(3) ) is amended by striking concurrently with, or at any time after, submission of an application for the investigation of the drug under section 505(i) of this Act or section 351(a)(3) of the Public Health Service Act and inserting at any point before or after submission of an application for approval of the drug under section 505(b) of this Act or licensure of the drug under section 351(a)(2) of the Public Health Service Act and shall include clinical evidence, including preliminary clinical evidence from clinical trials conducted outside of the United States .
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 307
Accelerating timeline for breakthrough and RMAT designations
Cites 1Cited by 0 across 0 sources